Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Cystic Fibrosis, Homozygous or Heterozygous for the F508del-CFTR Mutation”

8 trials

Showing 8 of 8 results

Large-scale testing (Phase 3)Study completedNCT05076149
What this trial is testing

VX-121 Combination Therapy in Participants With Cystic Fibrosis (CF) Who Are Homozygous for F508del, Heterozygous for F508del and a Gating (F/G) or Residual Function (F/RF) Mutation, or Have At Least 1 Other Triple Combination Responsive (TCR) CFTR Mutation and No F508del Mutation

Who this might be right for
Cystic Fibrosis
Vertex Pharmaceuticals Incorporated 597
Large-scale testing (Phase 3)Study completedNCT01931839
What this trial is testing

Rollover Study of Lumacaftor in Combination With Ivacaftor in Subjects 12 Years and Older With Cystic Fibrosis

Who this might be right for
Cystic Fibrosis, Homozygous or Heterozygous for the F508del-CFTR Mutation
Vertex Pharmaceuticals Incorporated 1,164
Large-scale testing (Phase 3)Study completedNCT02953314
What this trial is testing

Evaluate the Pharmacokinetics, Safety, and Tolerability of VX-661/Ivacaftor in Pediatric Subjects With Cystic Fibrosis (CF)

Who this might be right for
Cystic Fibrosis
Vertex Pharmaceuticals Incorporated 83
Testing effectiveness (Phase 2)Study completedNCT01531673
What this trial is testing

Study of VX-661 Alone and in Combination With Ivacaftor in Subjects Homozygous or Heterozygous to the F508del-Cystic Fibrosis Transmembrane Conductance Regulator(CFTR) Mutation

Who this might be right for
Cystic Fibrosis
Vertex Pharmaceuticals Incorporated 194
Large-scale testing (Phase 3)Study completedNCT03537651
What this trial is testing

Evaluate the Safety and Efficacy of Long-term Treatment With TEZ/IVA in CF Participants With an F508del CFTR Mutation

Who this might be right for
Cystic Fibrosis
Vertex Pharmaceuticals Incorporated 130
Large-scale testing (Phase 3)Study completedNCT03559062
What this trial is testing

Evaluate Efficacy and Safety of TEZ/IVA in Subjects Aged 6 Through 11 Years With Cystic Fibrosis

Who this might be right for
Cystic Fibrosis
Vertex Pharmaceuticals Incorporated 67
Testing effectiveness (Phase 2)Study completedNCT01225211
What this trial is testing

Study of VX-809 Alone and in Combination With VX-770 in Cystic Fibrosis (CF) Patients Homozygous or Heterozygous for the F508del-CFTR Mutation

Who this might be right for
Cystic Fibrosis
Vertex Pharmaceuticals Incorporated 312
Large-scale testing (Phase 3)Study completedNCT02565914
What this trial is testing

Evaluate the Safety and Efficacy of Long Term Treatment With VX-661 in Combination With Ivacaftor in Participants With Cystic Fibrosis Who Have an F508del-CFTR Mutation

Who this might be right for
Cystic Fibrosis
Vertex Pharmaceuticals Incorporated 1,131

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation